·重组人GALK2(N-乙酰半乳糖胺激酶) 编号:JN1066 英文名称:Recombinant Human N-acetylgalactosamine kinase 规格:10μg|50μg|500μg|1mg 本品由我们的哺乳动物细胞表达系统制备而成,目的基因编码的Met1-Ala458在C端含有His标签。
GALK2质量控制:>95%(还原性SDS-PAGE)
GALK2制剂:液体
GALK2保存:收到货后请置于-20℃,可保存6个月,避免反复冻融。
关于GALK2: GALK2 acts as a galactokinase when galactose is present at high concentrations. GALK2 may be involved in a salvage pathway for the reutilization of free GalNAc derived from the degradation of complex carbohydrates. GALK2 has been reported to participate in pathways , such as Amino sugar and nucleotide sugar metabolism, Galactose metabolism and Metabolic pathways.
·重组人PLA2G16(磷脂酶A2-XVI) 编号:JN0915 英文名称:Recombinant Human Phospholipase A2 Group XVI 规格:10μg|50μg|500μg|1mg 本品由我们的大肠杆菌表达系统制备而成,目的基因编码的Asp12-Asp132在N端含有His标签。
PLA2G16质量控制:>95%(还原性SDS-PAGE)
PLA2G16制剂:液体
PLA2G16保存:收到货后请置于-20℃,可保存6个月,避免反复冻融。
关于PLA2G16: Group XVI Phospholipase A1/A2 (PLA2G16) belongs to the H-rev 107 family. PLA2G16 is expressed in a number of human tumors including ovarian carcinomas, lung carcinomas. PLA2G16 is involved in the regulation of differentiation and survival. PLA2G16 regulates adipocyte lipolysis and release of fatty acids through a G-protein coupled pathway involving prostaglandin and EP3. It has also been reported to play a crucial role in the development of obesity in mouse models.
关于proVEGF-C: Vascular Endothelial Growth Factor (VEGF)-C is a member of the VEGF family, a group of polypeptide growth factors which play key roles in the physiology and pathology of many aspects of the cardiovascular system, including vasculogenesis, hematopoiesis, angiogenesis and vascular permeability. While VEGFC is homologous to other members of the VEGF/PDGF family, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGF signalling in endothelial cells occurs through three tyrosine kinase receptors (VEGFRs) expressed by endothelial cells and hematopoietic precursors, and VEGF-C is a ligand for two receptors, VEGFR-3 (Flt4), and VEGFR-2. It is indicated that VEGFC undergoes a complex proteolytic maturation generating a variety of processed secreted forms with increased activity toward VEGFR-3, but only the fully processed form could activate VEGFR-2. VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Knockout of the VEGF-C gene is embryonic lethal late in development, and although cells differentiate into the lymphatic lineage, they fail to sprout and form lymphatic vessels. Inactivation of a single VEGF-C allele results in the development of cutaneous lymphatic hypoplasia and lymphedema.